Relypsa's Phase III Fully Enrolled; Top-Line Data Next

Powers, Marie
May 2013
BioWorld Today;5/14/2013, Vol. 24 Issue 92, p1
The article reports that Relypsa Inc. has fully implemented its pivotal Phase III program of studying the efficacy and safety of non-absorbed oral potassium binder patiromer (RLY5016) in treating hyperkalemia in patients with chronic kidney disease. The study is being conducted under special protocol assessment with the U.S. Food and Drug Administration (FDA), and data is expected in the fall of 2013. The study enrolled 240 patients at more than 100 sites in the U.S., Europe, and Russia.


Related Articles

  • Relypsa Joins IPO Rush With a $126.5M Filing. Shaffer, Catherine // BioWorld Today;10/1/2013, Vol. 24 Issue 188, p1 

    The article reports that biotechnology company Relypsa Inc. filed for a 126.5 million U.S. dollar initial public offering (IPO) in October 2013. The IPO is aimed at improving the company's commercial operations for the launch of the patiromer drug, developed for potassium removal in the colon....

  • Relypsa Announces $80 Mln Private Financing Transaction.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Relypsa Inc. has announced 80 million U.S. dollar Series C preferred stock financing, which includes participation from both new and existing investors. It informs that the proceeds will be used by the company to fund late-stage development, submission of a new drug...

  • FDA accepts AstraZeneca's new Hyperkalaemia drug application for review.  // Pharma Focus Asia;10/18/2016, p2 

    The article highlights the decision of the U.S. Food and Drug Administration (FDA) to accept for review new drug application for sodium zirconium cyclosilicate (zs-9) for the treatment of Hyperkalaemia and cites the interactions with other health agencies in Australia and the European Union.

  • FDA issues safety advice on cefepime seizure risk.  // Reactions Weekly;7/7/2012, Issue 1409, p4 

    The article reports on the reminder issued by the U.S. Food and Drug Administration (FDA) to healthcare professionals regarding the need to adjust cefipime dosages in patients with renal impairment.

  • New FDA guidelines on clinical trials in women.  // Patient Care;11/15/1993, Vol. 27 Issue 18, p21 

    Reports on the United States Food and Drug Administration's guidelines on clinical trials in women. Drug development tests; Effects of concurrent medications on women; Drug applications.

  • A registry for clinical trials. Chollar, Susan // Annals of Internal Medicine;04/15/98, Vol. 128 Issue 8, p701 

    Presents information on the legalization of the United States Food and Drug Administration (FDA) Modernization Act of 1997 pertaining to a clinical trial registry. Information on the Public Law 105-115, Item 17: (82), Section 113; Forecast of the registry; Operation under the auspices of the...

  • FDA cites Johns Hopkins in asthma death.  // Medical Marketing & Media;Aug2001, Vol. 36 Issue 8, p32 

    Reports on the release of inspectional observations by the U.S. Food and Drug Administration for the Johns Hopkins Astham & Allergy Clinic in Baltimore, Maryland. Controversy over death following inhalation of hexamethonium; Failure of clinical investigator to submit required applications and...

  • FDA needs to better manage gender trail data.  // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p34 

    Reports on the need for the Food and Drug Administration to strengthen surveillance of gender differences in clinical trial data in the U.S. Evidence on gender bias in clinical trials; Citation of the agency recommending the policy.

  • Market Pulse.  // Pharmaceutical Executive;Feb2005, Vol. 25 Issue 2, p23 

    Presents a graph depicting the number of clinical trials approved by the U.S. Food and Drug Administration.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics